Skip to content

Chinese herbal formula Huoxiang Zhengqi for atopic dermatitis with dampness pattern (CHARM): a double-blinded randomized controlled trial

Postmarket research for two classical formulae of Chinese medicine based on an overarching design

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002679
Enrollment
Unknown
Registered
2019-10-19
Start date
2019-11-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eczema/atopic dermatitis

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of eczema/atpoic dermatitis; 2. Diagnosis of dampness pattern in Chinese Medicine; 3. aged 18-70 years; 4. 1% < BSA < 10%; 5. 1 <= IGA <= 3; 6. Signed Informed consent.

Exclusion criteria

Exclusion criteria: 1. Those with any uncontrolled cardiovascular, respiratory, digestive, urinary, hematological disease, known cancer or mental disease. 2. Those who has ever used Huoxiang Zhengqi Oral Liquid for treating eczema/atopic dermatitis. 3. Anyone allergic to any medicine or ingredients used in this study. 4. Examination result shows that ALT or AST level exceeded 2 times of the higher range value; either total bilirubin or BUN level exceeded 1.5 times of the higher range value in screening period. 5. Those who are pregnant, lactating, or who plan to become pregnant within 3 months. 6. Medication used: (1) Systemic therapy with immunomodulatory or immunosuppressive agents (including tripterygium wilfordii) within 4 weeks; (2) Topical or systematic therapy with antibiotics or antihistamines within 2 weeks; (3) Phototherapy (such as PUVA, UVA or UVB) within 4 weeks; (4) Topical therapy with immunomodulator within 2 weeks; (5) Topical or systematic used any over-the-counter drugs within a week. 7. Those who are participating in any clinical trial or had participated in clinical trial within a month. 8. Those who are considered not appropriate to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Eczema Area and Severity Index, EASI;

Secondary

MeasureTime frame
Body Surface Area,BSA;Investigator's Global Assessment, IGA;EQ-5D-5L;Numerical rating scale, NRS;Skindex-29;

Countries

China

Contacts

Public ContactZehuai Wen

Guangdong Provincial Hospital of Chinese Medicine

wenzh@gzucm.edu.cn+86 020-81887233-35838

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026